On July 27, 2026, STAT published an exclusive Health Care Inc. newsletter item by reporter Bob Herman that says the pharmaceutical industry’s primary lobbying organization, PhRMA, is attempting to steer public attention away from a clear rise in prescription drug spending. The article’s public excerpt states that industry lobbyists want readers to "ignore the clear-cut rise in prescription drug spending."
The item appears in STAT’s subscriber-only coverage labeled STAT+, and STAT placed the remainder of the story behind its paywall. The excerpt includes a general observation that lobbying groups commonly send news releases and talking points to journalists as a means of influencing reporting.
STAT’s publicly available text describes a familiar communications tactic: lobbying organizations frequently distribute prepackaged messages to journalists. The summary in the excerpt frames those materials as a channel through which industry advocates try to shape coverage of policy and spending issues. In this case, the claim is that PhRMA is pushing messaging intended to downplay or deflect attention from rising prescription drug costs.
The publicly accessible portion does not provide the specific talking points, the communications materials, or examples of the outreach campaign. It also does not include data, timelines, quoted sources, or responses from PhRMA in the excerpt that STAT posted without a subscription.
Bob Herman is identified in the article as STAT’s Business of Health Care reporter and the author of the Health Care Inc. newsletter. The profile notes that Herman covers the money side of health care, focusing on health insurance, hospitals, Medicare Advantage, and opaque prescription drug benefits. Contact information and links to his social profiles were included in the item.
The piece was presented as part of STAT’s Health Care Inc. newsletter. STAT labeled the article as a STAT+ exclusive, and the outlet promoted subscription access for readers who want the full reporting, in-depth analysis, and related subscriber benefits.
Because STAT made the story exclusive to STAT+ subscribers, the public excerpt omits significant details that would ordinarily be part of full reporting. The following were not reported in the visible portion of the article: specific examples of the communications PhRMA or other industry actors sent to journalists; any concrete evidence or data demonstrating the rise in prescription drug spending cited in the headline; timelines for the lobbying outreach; comments or rebuttals from PhRMA; named sources or documents; and any related policy or legal context. STAT’s paywall prevents confirmation of these elements from the publicly available text.
Readers should note that the publicly available passage contains a claim about messaging strategy and a broader statement about lobbying practices, but it does not supply the underlying materials or corroborating details in the excerpt.
The article’s headline and excerpt raise questions about how industry communications may shape public conversation on health care costs. The claim that PhRMA sought to deflect attention from rising prescription drug spending implies an interplay between advocacy tactics and reporting on health-care economics. The excerpt also reminds readers that journalists commonly receive prepackaged materials from interest groups — a routine but influential part of the information ecosystem.
However, because the bulk of the reporting, examples, and documentation are behind the STAT+ paywall, someone relying only on the free excerpt will not have access to the evidence necessary to evaluate the strength of the reporting or to trace the specific claims to sourced documents or interviews.
STAT flagged this story as an exclusive for STAT+ subscribers. The public page includes subscription options and prompts for readers who want to "unlock" the article along with other STAT+ features such as in-depth analysis, newsletters, premium events, and news alerts. The excerpt itself invited readers to subscribe or log in to read the rest of the story.
STAT’s publicly available excerpt asserts that PhRMA is attempting to influence public attention on prescription drug spending and reiterates that lobbying groups often send talking points to journalists. The piece was published on July 27, 2026, under STAT’s Health Care Inc. newsletter from reporter Bob Herman. Specific evidence, documents, direct quotations, and additional reporting referenced by STAT were not reported in the free excerpt and remain behind the outlet’s subscriber paywall. Readers who require the full set of facts, examples, and sources should consult the paid STAT+ version of the article.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.